Cocrystal Pharma Inc. has showcased its latest advancements in antiviral drug development through a recent investor presentation. The company is focusing on high-value antiviral drug targets, including influenza, norovirus, and coronaviruses, utilizing its proprietary drug discovery platform technology. Cocrystal Pharma is working on various clinical assets, such as the oral PB2 inhibitor CC-42344 for Influenza A and the first-in-class oral norovirus/coronavirus protease inhibitor CDI-988, which has shown favorable Phase 1 results. The company is also exploring pandemic preparedness collaboration opportunities and has a seasoned leadership team with experienced management and senior scientists, including two Nobel laureates. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。